Floatz logo

Irinotecan

Chemoradiotherapy

Fudan UniversitySmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

10 Active assets in the Chemoradiotherapy cohort.

Asset / SponsorPhaseRating
Carboplatin
Shanghai Chest Hospital
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
Shanghai Chest Hospital
Phase 3B
ETOPOSIDE
Shanghai Chest Hospital
Phase 3B
Capecitabine
National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos
Phase 2/3B
Eloxatin
Kangbuk Samsung Hospital
Phase 2B

View all 11 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →